Literaturverzeichnis Salicylsäure-Unverträglichkeit

Literatur zur Salicylsäure-Unverträglichkeit aus einer PubMed-Recherche zum Stand der Forschung zu Krankheitsbild, Pathogenese, Rolle von Salicalyten aus Lebensmitteln, Diagnose und Therapie der Samter-Trias im Frühahr 2018.

1. gelöscht
2. gelöscht
3. Sommer DD, Rotenberg BW, Sowerby LJ, Lee JM, Janjua A, Witterick IJ, Monteiro E, Gupta MK, Au M, Nayan S. A novel treatment adjunct for aspirin exacerbated respiratory disease: the low-salicylate diet: a multicenter randomized control crossover trial. Int Forum Allergy Rhinol. 2016 Apr;6(4):385-91.
4. gelöscht
5. Widal F, Abrami P, Lermoyez J. First complete description of the aspirin idiosyncrasy-asthma-nasal polyposis syndrome (plus urticaria)–1922 (with a note on aspirin desensitization). By F. Widal, P. Abrami, J. Lermoyez. J Asthma. 1987;24(5):297-300.
6. Kowalski ML, Makowska JS, Blanca M, Bavbek S, Bochenek G, Bousquet J, Bousquet P, Celik G, Demoly P, Gomes ER, Niżankowska-Mogilnicka E, Romano A, Sanchez-Borges M, Sanz M, Torres MJ, De Weck A, Szczeklik A, Brockow K. Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) – classification, diagnosis and management: review of the EAACI/ENDA and GA2LEN/HANNA. Allergy. 2011 Jul;66(7):818-29. doi: 10.1111/j.1398-9995.2011.02557.x.
7. Hans-Jochen Fiebig (21.12.2011): Fettsäurezusammensetzung wichtiger pflanzlicher und tierischer Speisefette und -öle [online] http://www.dgfett.de/material/fszus.php [25.01.2018].
8. gelöscht
9. gelöscht
10. Samter M, Beers RF Jr. Concerning the nature of intolerance to aspirin. J Allergy. 1967 Nov;40(5):281-93.
11. Samter M, Beers RF Jr. Intolerance to aspirin. Clinical studies and consideration of its pathogenesis. Ann Intern Med. 1968 May;68(5):975-83.
12. Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma. Eur Respir J. 2000 Sep;16(3):432-6.
13. Berges-Gimeno MP, Simon RA, Stevenson DD. The natural history and clinical characteristics of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2002 Nov;89(5):474-8.
14. Ertoy Karagol HI, Yilmaz O, Topal E, Ceylan A, Bakirtas A. Nonsteroidal anti-inflammatory drugs-exacerbated respiratory disease in adolescents. Int Forum Allergy Rhinol. 2015 May;5(5):392-8.
15. Young J, Frenkiel S, Tewfik MA, Mouadeb DA. Long-term outcome analysis of endoscopic sinus surgery for chronic sinusitis. Am J Rhinol. 2007 Nov-Dec;21(6):743-7. doi: 10.2500/ajr.2007.21.3108.
16. Kim JE, Kountakis SE. The prevalence of Samter’s triad in patients undergoing functional endoscopic sinus surgery. Ear Nose Throat J. 2007 Jul;86(7):396-9.
17. Bochenek G, Niżankowska-Mogilnicka E. Aspirin-exacerbated respiratory disease: clinical disease and diagnosis. Immunol Allergy Clin North Am. 2013 May;33(2):147-61.
18. Amar YG, Frenkiel S, Sobol SE. Outcome analysis of endoscopic sinus surgery for chronic sinusitis in patients having Samter’s triad. J Otolaryngol 2000;29:7-12
19. Batra PS, Kern RC, Tripathi A, et al. Outcome analysis of endoscopic sinus surgery in patients with nasal polyps and asthma. Laryngoscope 2003;113:1703-6 33.
20. Janti-Alanko S, Holopainen E, Malmberg H. Recurrence of nasal polyps after surgical treatment. Rhinol Suppl 1989;8:59-64.
21. McFadden EA, Kany RJ, Fink JN, et al. Surgery for sinusitis and aspirin triad. Laryngoscope 1990;100:1043-6.
22. McMains KC, Kountakis SE. Medical and surgical considerations in patients with Samter’s triad. Am J Rhinol. 2006 Nov-Dec;20(6):573-6.
23. Vento SI, Ertama LO, Hytonen ML, et al. Nasal polyposis: clinical course during 20 years. Ann Allergy Asthma Immunol 2000;85:209-14.
24. Mascia K, Borish L, Patrie J, Hunt J, Phillips CD, Steinke JW. Chronic hyperplastic eosinophilic sinusitis as a predictor of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2005 Jun;94(6):652-7.
25. The ENFUMOSA cross-sectional European multicentre study of the clinical phensotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J. 2003 Sep;22(3):470-7.
26. Shah NH, Schneider TR, DeFaria Yeh D, Cahill KN, Laidlaw TM. Eosinophilia-Associated Coronary Artery Vasospasm in Patients with Aspirin-Exacerbated Respiratory Disease. J Allergy Clin Immunol Pract. 2016 Nov – Dec;4(6):1215-1219.
27. Stevens W, Buchheit K, Cahill KN. Aspirin-Exacerbated Diseases: Advances in Asthma with Nasal Polyposis, Urticaria, Angioedema, and Anaphylaxis. Curr Allergy Asthma Rep. 2015 Dec;15(12):69.
28. Cahill KN, Bensko JC, Boyce JA, Laidlaw TM. Prostaglandin D₂: a dominant mediator of aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2015 Jan;135(1):245-52.
29. Johns CB, Laidlaw TM. Elevated total serum IgE in nonatopic patients with aspirin-exacerbated respiratory disease. Am J Rhinol Allergy. 2014 Jul-Aug;28(4):287-9.
30. Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis and management. J Allergy Clin Immunol. 1999 Jul;104(1):5-13.
31. Ta V, White AA. Survey-Defined Patient Experiences With Aspirin-Exacerbated Respiratory Disease. J Allergy Clin Immunol Pract. 2015 Sep-Oct;3(5):711-8.
32. Molderings G, Homann J, Brettner S, Raithel M, Frieling T. Systemische Mastzellaktivierungserkrankung: Ein praxisorientierter Leitfaden zu Diagnostik und Therapie. DMW – Deutsche Medizinische Wochenschrift. 2014;139:1523-1538.
33. Pöhlau D, Raithel M, Haenisch B, Harzer S, Molderings, G. Neurologische und psychiatrische Symptome der systemischen MCAD. NeuroTransmitter. 2015;26:46-50.
34. Laidlaw TM, Cahill KN. Current Knowledge and Management of Hypersensitivity to Aspirin and NSAIDs. J Allergy Clin Immunol Pract. 2017 May – Jun;5(3):537-545.
35. Kowalski ML, Woessner K, Sanak M. Approaches to the diagnosis and management of patients with a history of nonsteroidal anti-inflammatory drug-related urticaria and angioedema. J Allergy Clin Immunol. 2015 Aug;136(2):245-51. doi: 10.1016/j.jaci.2015.06.021.
36. Sánchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A, González-Aveledo L. Aspirin-exacerbated cutaneous disease (AECD) is a distinct subphenotype of chronic spontaneous urticaria. J Eur Acad Dermatol Venereol. 2015 Apr;29(4):698-701. doi: 10.1111/jdv.12658.
37. Mastalerz L, Setkowicz M, Szczeklik A. Mechanism of chronic urticaria exacerbation by aspirin. Curr Allergy Asthma Rep. 2005 Jul;5(4):277-83.
38. Stevenson DD, Sanchez-Borges M, Szczeklik A. Classification of allergic and pseudoallergic reactions to drugs that inhibit cyclooxygenase enzymes. Ann Allergy Asthma Immunol. 2001 Sep;87(3):177-80.
39. Morales DR, Guthrie B, Lipworth BJ, Jackson C, Donnan PT, Santiago VH. NSAID-exacerbated respiratory disease: a meta-analysis evaluating prevalence, mean provocative dose of aspirin and increased asthma morbidity. Allergy. 2015 Jul;70(7):828-35. doi: 10.1111/all.12629.
40. Rajan JP, Wineinger NE, Stevenson DD, White AA. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature. J Allergy Clin Immunol. 2015 Mar;135(3):676-81.e1. doi: 10.1016/j.jaci.2014.08.020.
41. Mahdavinia M, Benhammuda M, Codispoti CD, Tobin MC, Losavio PS, Mehta A, Jeffe JS, Bandi S, Peters AT, Stevens WW, Landay A, Keshavarzian A, Schleimer RP, Batra PS. African American Patients with Chronic Rhinosinusitis Have a Distinct Phenotype of Polyposis Associated with Increased Asthma Hospitalization. J Allergy Clin Immunol Pract. 2016 Jul-Aug;4(4):658-664.e1.
42. Robert Koch-Institut (Hg.). Asthma bronchiale. Faktenblatt zu GEDA 2012: Ergebnisse der Studie »Gesundheit in Deutschland aktuell 2012« (Stand: 08.04.2015). [online] https://www.rki.de/DE/Content/Gesundheitsmonitoring/Gesundheitsberichterstattung/GBEDownloadsF/Geda2012/Asthma_bronchiale.pdf?__blob=publicationFile [20.03.2018].
43. Horn F. Biochemie des Menschen: Das Lehrbuch für das Medizinstudium, 5. korrigierte Auflage. Stuttgart, New York: Thieme Verlag 2012.
44. NEUROtiker (21.11.2007): Struktur von Arachidonsäure (5,8,11,14-Eicosatetraensäure) [online] https://commons.wikimedia.org/wiki/File:Arachidonsäure2.svg [06.03.2018]
45. Szczeklik A, Gryglewski RJ, Czerniawska-Mysik G. Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients. Br Med J 1975;1:67-9.
46. Szczeklik A. The cyclooxygenase theory of aspirin-induced asthma. Eur Respir J 1990;3:588-93.
47. Szczeklik A, Gryglewski RJ, Czerniawska-Mysik G. Participation of prostaglandins in pathogenesis of aspirin-sensitive asthma. Naunyn Schmiedeberg’s Arch Pharmacol. 1977;297 Suppl 1:S99– 10.
48. Szczeklik A, Gryglewski RJ, Olszewski E, Dembińska-Kiec A, Czerniawska-Mysik G. Aspirin-sensitive asthma: the effect of aspirin on the release of prostaglandins from nasal polyps. Pharmacol Res Commun. 1977 May;9(5):415-25.
49. Sladek K, Szczeklik A. Cysteinyl leukotrienes overproduction and mast cell activation in aspirin-provoked bronchospasm in asthma. Eur Respir J. 1993;6(3):391–9.
50. Laidlaw TM, Boyce JA. Aspirin-Exacerbated Respiratory Disease–New Prime Suspects. N Engl J Med. 2016 Feb 4;374(5):484-8.
51. Laidlaw TM, Kidder MS, Bhattacharyya N, Xing W, Shen S, Milne GL, Castells MC, Chhay H, Boyce JA. Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes. Blood. 2012 Apr 19;119(16):3790-8.
52. Laidlaw TM, Boyce JA. Platelets in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2015 Jun;135(6):1407-14; quiz 1415.
53. Cahill KN, Boyce JA. Aspirin-exacerbated respiratory disease: Mediators and mechanisms of a clinical disease. J Allergy Clin Immunol. 2017 Mar;139(3):764-766.
54. Rodríguez-Jiménez JC, Moreno-Paz FJ, Terán LM, Guaní-Guerra E. Aspirin exacerbated respiratory disease: Current topics and trends. Respir Med. 2018 Feb;135:62-75.
55. Yoo HS, Shin YS, Liu JN, Kim MA et al (2013) Clinical significance of immunoglobulin E responses to staphylococcal superantigens in patients with aspirin-exacerbated respiratory disease. Int Arch Allergy Immunol 162(4):340–345.
56. Sakalar EG, Muluk NB, Kar M, Cingi C. Aspirin-exacerbated respiratory disease and current treatment modalities. Eur Arch Otorhinolaryngol. 2017 Mar;274(3):1291-1300.
57. Fruth K, Gosepath J. Aspirin Exacerbated Respiratory Disease. Adv Otorhinolaryngol. 2016;79:21-8.
58. Garon SL, Pavlos RK, White KD, Brown NJ, Stone CA Jr, Phillips EJ. Pharmacogenomics of off-target adverse drug reactions. Br J Clin Pharmacol. 2017 Sep;83(9):1896-1911.
59. Shin S, Park JS, Kim YJ, Oh T, An S, Park CS. Differential gene expression profile in PBMCs from subjects with AERD and ATA: a gene marker for AERD. Mol Genet Genomics. 2012 May;287(5):361-71.
60. Belitz H-D, Grosch W, Schieberle P. Lehrbuch der Lebensmittelchemie : mit 620 Tabellen, 5., vollst. überarb. Auflage. Berlin: Springer 2001.
61. NEUROtiker (14.12.2007): Struktur von Benzoesäure. [online] https://commons.wikimedia.org/wiki/File:Benzoesäure.svg [06.03.2018]
62. Fvasconcellos (nach Benjah-bmm27 and Booyabazooka) (07.01.2007): Skeletal formula of salicylic acid. [online]
    https://commons.wikimedia.org/wiki/File:Salicylic-acid-skeletal.svg
    [06.03.2018]
63. Duthie GG, Wood AD. Natural salicylates: foods, functions and disease prevention. Food Funct. 2011 Sep;2(9):515-20.
64. Ebermann R, Elmadfa I. Lehrbuch Lebensmittelchemie und Ernährung, 2. Auflage. Wien: Springer 2011.
65. Regulation (EC) No 1333/2008, Annex II
66. Hamburger Lebensmittelstiftung (o.J.): Lexikon der Zusatzsstoffe – Salicylsäure. [online] https://www.zusatzstoffmuseum.de/lexikon-der-zusatzstoffe/salicylsaeure.html [02.03.2018].
67. NEUROtiker (24.06.2008): Struktur von Acetylsalicylsäure. [online] https://de.wikipedia.org/wiki/Datei:Acetylsalicylsäure2.svg [06.03.2018]
68. Amann R, Peskar BA. Anti-inflammatory effects of aspirin and sodium salicylate. Eur J Pharmacol. 2002; 447: 1-9.
69. Rietbrock N, Staib AH, Loew D (Hrsg.): Klinische Pharmakologie: Ein Leitfaden für die Praxis. Heidelberg: Steinkopff-1996.
70. Swain AR: The Role of Natural Salicylates in Food Intolerance. A thesis submitted for the degree of Doctor of Philosophy in the University of Sidney. 1988.
71. Venema DP, Hollman P, Janssen KPLTMK, Katan MB. Determination of Acetylsalicylic Acid and Salicylic Acid in Foods, Using HPLC with Fluorescence Detection. Journal of Agricultural and Food Chemistry 1996;44: 1762-1767.
72. Aresta A, Zambonin C. Simultaneous determination of salicylic, 3-methylsalicylic, 4-methyl salicylic, acetylsalicylic and benzoic acids in fruit, vegetables and derived beverages by SPME-LC-UV/DAD. J Pharm Biomed Anal. 2016 Mar 20;121:63-68.
73. Giménez MJ, Serrano M, Valverde JM, Martínez-Romero D, Castillo S, Valero D, Guillén F. Preharvest salicylic acid and acetylsalicylic acid treatments preserve quality and enhance antioxidant systems during postharvest storage of sweet cherry cultivars. J Sci Food Agric. 2017 Mar;97(4):1220-1228.
74. Iben B. Entzündungen und nichtsteroidale Antiphlogistika. Großtierpraxis 2011;12(12):520-527.
75. Bernemann U. Orale NSAIDs – Mehr als nur Verbesserung des Tierwohls. Großtierpraxis 2012;13(01):6-11.
76. Hare LG, Woodside JV, Young IS. Dietary salicylates. J Clin Pathol. 2003; 56: 649-650.Picado C, Fernandez-Morata JC, Juan M, Roca-Ferrer J, Fuentes M, Xaubet A, Mullol J. Cyclooxygenase-2 mRNA is downexpressed in nasal polyps from aspirin-sensitive asthmatics. Am Resp Crit Care Med. 1999; 160: 291-296.
77. Mitchell JE, Skypala I. Aspirin and salicylate in respiratory disease. Rhinology. 2013 Sep;51(3):195-205.
78. Wood A, Baxter G, Thies F, Kyle J, Duthie G. A systematic review of salicylates in foods: estimated daily intake of a Scottish population. Mol Nutr Food Res. 2011 May;55 Suppl 1:S7-S14.
79. Swain AR, Dutton SP, Truswell AS. Salicylates in Foods. J Am Diet Assoc. 1985; 85: 950-960.
80. Swain A, Soutter V, Loblay R. RPAH Elimination Diet Handbook: with food & shopping guide, Revised edition. Sidney: Allergy Unit, Royal Prince Albert Hospital, 2011. 51-56
81. Janssen PL, Hollman PC, Reichman E, Venema DP, van Staveren WA, Katan MB. Urinary salicylate excretion in subjects eating a variety of diets shows that amounts of bioavailable salicylates in foods are low. Am J Clin Nutr. 1996 Nov;64(5):743-7.
82. Blacklock CJ, Lawrence JR, Malcolm EA, et al. Salicylic acid in the serum of subjects not taking aspirin. Comparison of salicylic acid concentrations in the serum of vegetarians, non-vegetarians, and patients taking low-dose aspirin. J Clin Pathol. 2001;54:553–5.
83. Lawrence JR, Peter R, Baxter GJ, Robson J, Graham AB, Paterson JR. Urinary excretion of salicyluric and salicylic acids by non-vegetarians, vegetarians, and patients taking low dose aspirin. J Clin Pathol. 2003 Sep;56(9):651-3.
84. Paterson JR, Srivastava R, Baxter GJ, Graham AB, Lawrence JR. Salicylic acid content of spices and its implications. J Agric Food Chem. 2006 Apr 19;54(8):2891-6.
85. Janssen PL, Hollman PC, Venema DP, van Staveren WA, Katan MB. Salicylates in foods. Nutr Rev. 1996 Nov;54(11 Pt 1):357-9.
86. Wood A, Baxter G, Paterson J, Thies F, Duthie G. Comparison of methods to determine salicylic acid content of fruit juices. Proc Nutr Soc. 2005; 64: 87A.
87. Baxter G J, Graham AB, Lawrence JR, Wiles D, Paterson JR. Salicylic acid in soups prepared from organically and non-organically grown vegetables. Eur J Nutr. 2001; 40: 289-292.
88. Heiska S, Rousi M, Turtola S, Meier B, Tirkkonen V, Julkunen-Titto R. The effect of genotype and cultivation method on the total salicylate yield of dark leaved willows. Plant Medica. 2005; 71: 1134-1139.
89. Esmaeilzedeh H, Esmaeilzadeh E, Faramarzi M, Nabavi M, Farhadi M. Salicylate Food Intolerance and Aspirin Hypersensitivity in Nasal Polyposis. Iran J Immunol. 2017 Mar;14(1):81-88. doi: IJIv14i1A8.
90. Nizankowska-Mogilnicka E, Bochenek G, Mastalerz L, Swierczyńska M, Picado C, Scadding G, Kowalski ML, Setkowicz M, Ring J, Brockow K, Bachert C, Wöhrl S, Dahlén B, Szczeklik A. EAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity. Allergy. 2007 Oct;62(10):1111-8.
91. Dahl R. Sodium salicylate and aspirin disease. Allergy. 1980 Mar;35(2):155-6.
92. Dahlén B, Boréus LO, Anderson P, Andersson R, Zetterström O. Plasma acetylsalicylic acid and salicylic acid levels during aspirin provocation in aspirin-sensitive subjects. Allergy. 1994; 49:43-49.
93. Corder EH, Buckley CE. Aspirin, salicylate, sulfite and tartrazine-induced bronchoconstriction. Safe doses and case definition in epidemiological studies. J Clin Epidemiol. 1995; 48: 1269-1275.
94. Eriksson NE. Food sensitivity reported by patients with asthma and hay fever. A relationship between food sensitivity and birch pollen-allergy and between food sensitivity and acetylsalicylic acid intolerance. Allergy. 1978 Aug;33(4):189-96.
95. Cardet JC, White AA, Barrett NA, Feldweg AM, Wickner PG, Savage J, Bhattacharyya N, Laidlaw TM. Alcohol-induced respiratory symptoms are common in patients with aspirin exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2014 Mar-Apr;2(2):208-13..
96. Calais CJ, Banks TA. Resolution of alcohol-induced respiratory symptoms following aspirin desensitization in aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2015 May;114(5):429-30.
97. Vally H, de Klerk N, Thompson PJ. Alcoholic drinks: important triggers for asthma. J Allergy Clin Immunol. 2000 Mar;105(3):462-7.
98. Reese I, Zuberbier T, Bunselmeyer B, Erdmann S, Henzgen M, Fuchs T, Jäger L, Kleine-Tebbe J, Lepp U, Niggemann B, Raithel M, Saloga J, Vieths S, Werfel T. Diagnostisches Vorgehen bei Verdacht auf eine pseudoallergische Reaktion durch Nahrungsmittelinhaltsstoffe: Leitlinien der Deutschen Gesellschaft Allergologie und klinische Immunologie (DGAKI), des Ärzteverbandes Deutscher Allergologen (ÄDA) und der Gesellschaft für Pädiatrische Allergologie (GPA). Allergo J. 2008(17):540-49.
99. Raithel M, Baenkler HW, Naegel A, Buchwald F, Schultis HW, Backhaus B, Kimpel S, Koch H, Mach K, Hahn EG, Konturek PC. Significance of salicylate intolerance in diseases of the lower gastrointestinal tract. J Physiol Pharmacol. 2005 Sep;56 Suppl 5:89-102.
100. Sommer DD, Rotenberg BW, Sowerby LJ, Lee JM, Janjua A, Witterick IJ, Monteiro E, Gupta MK, Au M, Nayan S. A novel treatment adjunct for aspirin exacerbated respiratory disease: the low-salicylate diet: a multicenter randomized control crossover trial. Int Forum Allergy Rhinol. 2016 Apr;6(4):385-91. doi: 10.1002/alr.21678.
101. Juhlin L, Michaëlsson G, Zetterström O. Urticaria and asthma induced by food-and-drug additives in patients with aspirin hypersensitivity. J Allergy Clin Immunol. 1972 Aug;50(2):92-8.
102. Settipane GA, Pudupekkam RK: Aspirin Intolerance. Ill. Subtypes, familial occurrence and cross-reactivity with tartrazine. J Allergy Clin lmmunol 1975; 56: 215.
103. Rosenhall L, Zetterström O. Proceedings: Asthmatic patients with hypersensitivity to aspirin, benzoic acid and tartrazine. Tubercle. 1975 Jun;56(2):168.
104. Delaney JC: Response of patients with asthma and aspirin idiosyncrasy to tartrazine (a dye commonly used in the food and drug inustries). Practitioner 1976; 217: 285.
105. Stenius BSM, Lemola M: Hypersensitivity to acetylsalicylic acid (ASA) and tartrazine in patients with asthma. Clin Allergy 6:119, 1976
106. Grzelewska-Rzymowska I, Szmidt M, Kowalski ML, Roźniecki J. Sensitivity and tolerance to tartrazine in aspirin-sensitive asthmatics. Allergol Immunopathol (Madr). 1986 Jan-Feb;14(1):31-6.
107. Morales MC, Basomba A, Pelaez A, Garcia Villalmanzo I, Campos A. Challenge tests with tartrazine in patients with asthma associated with intolerance to analgesics (ASA-Triad). A comparative study with placebo. Clin Allergy. 1985 Jan;15(1):55-9.
108. Williams WR, Pawlowicz A, Davies BH. Aspirin-like effects of selected food additives and industrial sensitizing agents. Clin Exp Allergy. 1989 Sep;19(5):533-7.
109. Settipane GA. Aspirin and allergic diseases: a review. Am J Med. 1983 Jun 14;74(6A):102-9.
110. Juhlin L. Incidence of intolerance to food additives. Int J Dermatol. 1980 Dec;19(10):548-51.
111. Simon RA, Dazy KM, Waldram JD. Aspirin-exacerbated respiratory disease: characteristics and management strategies. Expert Rev Clin Immunol. 2015;11(7):805-17.
112. Makowska J, Lewandowska-Polak A, Kowalski ML. Hypersensitivity to Aspirin and other NSAIDs: Diagnostic Approach in Patients with Chronic Rhinosinusitis. Curr Allergy Asthma Rep. 2015 Aug;15(8):47.
113. Randerath WJ. Das Analgetika-Asthma-Syndrom. Dtsch Med Wochenschr. 2013 Mar;138(11):541-7. doi: 10.1055/s-0032-1332934.
114. Macy E, Bernstein JA, Castells MC, Gawchik SM, Lee TH, Settipane RA, Simon RA, Wald J, Woessner KM; Aspirin Desensitization Joint Task Force. Aspirin challenge and desensitization for aspirin-exacerbated respiratory disease: a practice paper. Ann Allergy Asthma Immunol. 2007 Feb;98(2):172-4.
115. Brockow K, Przybilla B, Aperer W, Bircher AJ, Breheler R, Dickel H, Fuchs T, Jakob T, Lange L, Pfützen W, Mockenhaupt M, Ott H, Pfaar O, Ring J, Sachs B, Sitter H, Trautmann A, Trödler R, Weda B, Worm M, Wurpts G, Zuberbier T, Merk HF. Leitlinie Allergologische Diagnostik von Überempfindlichkeitsreaktionen auf Arzneimittel: S2K-Leitlinie der Deutschen Gesellschaft für Allergologie und klinische Immunologie (DGAKI) und der Deutschen Dermatologischen Gesellschaft (DDG) in Zusammenarbeit mit dem Ärzteverband Deutscher Allergologen (AeDA), der Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA), der Deutschen Kontaktallergiegruppe (DKG), der Schweizerischen Gesellschaft für Allergologie und Immunologie (SGAI), der Österreichischen Gesellschaft für Allergologie und Immunologie (ÖGAI), der Deutschen Akademie für Allergologie und Umweltmedizin (DAAU), dem Dokumentationszentrum für schwere Hautreaktionen und dem Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM). Allergo J. 2015(24:94): 44-55.
116. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Asthma – Langfassung, 2. Auflage. Version 5. 2009, zuletzt geändert: August 2013., [online] http://www.versorgungsleitlinien.de/themen/asthma [14.06.2017]; doi: 10.6101/AZQ/000163.
117. Stuck BA, Popert U, Beule A, Jobst D, Klimek L, Laudien M, Lell M, Vogl T. Leitlinie „Rhinosinusitis“ – Langfassung: S2k-Leitlinie der Deutschen Gesellschaft für Allgemeinmedizin und Familienmedizin und der Deutschen Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie e. V.. HNO. [online] http://www.awmf.org/uploads/tx_szleitlinien/017-049_und_053-012l_S2k_Rhinosinusitis_2017-12.pdf [12.01.2018].
118. Charité, Klinik für Hals-Nasen-Ohrenheilkunde, Campus Benjamin Franklin, Dr. med. Dipl. Biochem. Veit Hofmann. Informationsblatt für Patienten zur nasalen Provokationstestung und anschließenden adaptiven Desaktivierung (o.J.). [online] https://hno-klinik.charite.de/fileadmin/user_upload/microsites/m_cc16/hno-klinik/Dokumente/3Patienteninformationsbogen_zur_Nasalen_Provokationstestung_mit_ASS_und_anschlie%c3%9fenden_Adaptiven_Desaktivierung.pdf [20.03.2018].
119. Mühlmeier G, Hausch R, Maier H. Adaptive Desaktivierung bei ASS-Hypersensitivität – Eine Erfolgsgeschichte? HNO 2015(63): 707.
120. Schäfer D, Maune S. Pathogenic Mechanisms and In Vitro Diagnosis of AERD. J Allergy (Cairo). 2012;2012:789232.
121. Dollner R, Hörmann K, Stuck BA, Pfaar O, Klimek L. In-vitro-Diagnostik des ASS-Intoleranz-Syndroms (Aspirin-exacerbated Respiratory Disease AERD). Allergologie 2014;37(01):11–19.
122. Baenkler HW. Salicylatintoleranz: Pathophysiologie, klinisches Spektrum, Diagnostik und Therapie. Deutsches Ärzteblatt 2008; 105(8): 137-42.
123. Gosepath, Schäfer, Mann. Analgetika-Intoleranz: Langzeitergebnisse bis zu 3 Jahren bei adaptiver Desaktivierung mit einer täglichen Erhaltungsdosis von 100 mg Aspirin. Laryngo-Rhino-Otol 2002; 81(10): 732-738.
124. Fruth K, Pogorzelski B, Schmidtmann I, Springer J, Fennan N, Fraessdorf N, Boessert A, Schaefer D, Gosepath J, Mann WJ. Low-dose aspirin desensitization in individuals with aspirin-exacerbated respiratory disease. Allergy. 2013;68(5):659-65.
125. Hagan JB, Laidlaw TM, Divekar R, O’Brien EK, Kita H, Volcheck GW, Hagan CR, Lal D, Teaford HG 3rd, Erwin PJ, Zhang N, Rank MA. Urinary Leukotriene E4 to Determine Aspirin Intolerance in Asthma: A Systematic Review and Meta-Analysis. J Allergy Clin Immunol Pract. 2017 Jul – Aug;5(4):990-997.e1.
126. Shin S, Park JS, Kim YJ, Oh T, An S, Park CS. Differential gene expression profile in PBMCs from subjects with AERD and ATA: a gene marker for AERD. Mol Genet Genomics. 2012 May;287(5):361-71.
127. Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, Cohen N, Cervin A, Douglas R, Gevaert P, Georgalas C, Goossens H, Harvey R, Hellings P, Hopkins C, Jones N, Joos G, Kalogjera L, Kern B, Kowalski M, Price D, Riechelmann H, Schlosser R, Senior B, Thomas M, Toskala E, Voegels R, Wang de Y, Wormald PJ. European Position Paper on Rhinosinusitis and Nasal Polyps 2012. Rhinol Suppl. 2012 Mar;(23):3 p preceding table of contents, 1-298.
128. Umbreit C., Virchow JC, Thorn C, Hörmann K, Klimek L, Pfaar O. Analgetikaintoleranz – Ein häufiges, interdisziplinäres Krankheitsbild. Internist, 2010(51): 1196-1201.
129. Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol. 2003;111:913-921.
130. Awad OG, Lee JH, Fasano MB, et al. Sinonasal outcomes after endoscopic sinus surgery in asthmatic patients with nasal polyps: a difference between aspirin-tolerant and aspirin-induced asthma? Laryngoscope 2008;118(7):1282-6.
131. Zeiss CR, Lockey RF. Refractory period to aspirin in a patient with aspirin-induced asthma. J Allergy Clin Immunol. 1976 May;57(5):440-8.
132. Stevenson DD, Hankammer MA, Mathison DA, Christiansen SC, Simon RA. Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis-asthma: long-term outcomes. J Allergy Clin Immunol. 1996 Oct;98(4):751-8.
133. White AA, Stevenson DD. Aspirin-exacerbated respiratory disease: update on pathogenesis and desensitization. Semin Respir Crit Care Med. 2012 Dec;33(6):588-94.
134. Klimek L, Dollner R, Pfaar O, Mullol J. Aspirin desensitization: useful treatment for chronic rhinosinusitis with nasal polyps (CRSwNP) in aspirin-exacerbated respiratory disease (AERD)? Curr Allergy Asthma Rep 2014(6):441.
135. Weber R, Trautmann A, Randerath W, Heppt W, Hosemann W. ASS-Toleranzinduktion. Therapieoption bei Patienten mit analgetikainduzierter Erkrankung der Atemwege. HNO 2012;60(4):369–383.
136. Peters AT, Spector S, Hsu J, Hamilos DL, Baroody FM, Chandra RK, Grammer LC, Kennedy DW, Cohen NA, Kaliner MA, Wald ER, Karagianis A, Slavin RG; Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma and Immunology, the American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology. Diagnosis and management of rhinosinusitis: a practice parameter update. Ann Allergy Asthma Immunol. 2014 Oct;113(4):347-85.
137. Kennedy JL, Stoner AN, Borish L. Aspirin-exacerbated respiratory disease: Prevalence, diagnosis, treatment, and considerations for the future. Am J Rhinol Allergy. 2016 Nov 1;30(6):407-413.
138. Kassenärztliche Bundesvereinigung (KBV). Beschluss des Gemeinsamen Bundesauusschusses über die Änderung der Arzneimittel-Richtlinie in Anlage 4: Therapiehinweis zu Montelukast vom 15. November 2007. Dtsch Arztebl 2008; 105(18): A-966 / B-842 / C-822.
139. Holgate ST, Bradding P, Sampson AP. Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy. J Allergy Clin Immunol. 1996 Jul;98(1):1-13.
140. Schäper C, Noga O, Koch B, Ewert R, Felix SB, Gläser S, Kunkel G, Gustavus B. Anti-inflammatory properties of montelukast, a leukotriene receptor antagonist in patients with asthma and nasal polyposis. J Investig Allergol Clin Immunol. 2011;21(1):51-8.
141. Pauli C, Fintelmann R, Klemens C, Hilgert E, Jund F, Rasp G, et al. Polyposis nasi- -improvement in quality of life by the influence of leukotrien receptor antagonists. Laryngorhinootologie. 2007 Apr;86(4):282-6.
142. Mostafa BE, Hay HA, Mohammed HE, Yamani M. Role of leukotriene inhibitors in the postoperative management of nasal polyps. Orl. 2005;67(3):148-53.
143. Vuralkan E, Saka C, Akin I, et al. Comparison of montelukast and mometasone furoate in the prevention of recurrent nasal polyps. Ther Adv Respir Dis 2012;6:5–10.
144. Mastalerz L, Nizankowska E, Sanak M, Mejza F, Pierzchalska M, Bazan-Socha S, Bestynska-Krypel A, et al. Clinical and genetic features underlying the response of patients with bronchial asthma to treatment with a leukotriene receptor antagonist. Eur J Clin Invest 2002;32:949–955.
145. Stewart RA, Ram B, Hamilton G, Weiner J, Kane KJ. Montelukast as an adjunct to oral and inhaled steroid therapy in chronic nasal polyposis. Otolaryngol Head Neck Surg. 2008 Nov;139(5):682-7.
146. Dahlén SE, Malmström K, Nizankowska E, Dahlen B, Kuna P, Kowalski M, Lumry WR, et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:9–14.
147. Philip G, Villarán C, Shah SR, Vandormael K, Smugar SS, Reiss TF. The efficacy and tolerability of inhaled montelukast plus inhaled mometasone compared with mometasone alone in patients with chronic asthma. Asthma. 2011 Jun;48(5):495-502.
148. Chauhan BF, Jeyaraman MM, Singh Mann A, Lys J, Abou-Setta AM, Zarychanski R, Ducharme FM. Addition of anti-leukotriene agents to inhaled corticosteroids for adults and adolescents with persistent asthma. Cochrane Database Syst Rev. 2017 Mar 16;3:CD010347.
149. Joos S, Miksch A, Szecsenyi J, Wieseler B, Grouven U, Kaiser T, Schneider A. Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review. Thorax. 2008 May;63(5):453-62.
150. Pinto JM, Mehta N, DiTineo M, Wang J, Baroody FM, Naclerio RM (2010) A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis. Rhinology 48(3):318–324.
151. Gevaert P, Calus L, Van Zele T, Blomme K, De Ruyck N, Bauters W, Hellings P, Brusselle G, De Bacquer D, van Cauwenberge P, Bachert C. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013 Jan;131(1):110-6.e1.
152. Biesalski HK, Pirlich M, Bischoff SC, Weimann A (Hrgs.) Ernährungsmedizin – Nach dem neuen Curriculum Ernährungsmedizin der Bundesärztekammer und der DGE, 5., vollständig überarbeitete und erweiterte Auflage. Stuttgart, New York: Georg Thieme Verlag, 2017.
153. Sommer DD, Hoffbauer S, Au M, Sowerby LJ, Gupta MK, Nayan S. Treatment of aspirin exacerbated respiratory disease with a low salicylate diet: a pilot crossover study. Otolaryngol Head Neck Surg. 2015 Jan;152(1):42-7.
154. Levy JM, Rudmik L, Peters AT, Wise SK, Rotenberg BW, Smith TL. Contemporary management of chronic rhinosinusitis with nasal polyposis in aspirin exacerbated respiratory disease: an evidence-based review with recommendations. International forum of allergy & rhinology. 2016;6(12):1273-1283.
155. Buchheit KM, Laidlaw TM. Update on the Management of Aspirin-Exacerbated Respiratory Disease. Allergy Asthma Immunol Res. 2016 Jul;8(4):298-304.
156. Nayan S, Maby A, Endam LM, Desrosiers M. Dietary modifications for refractory chronic rhinosinusitis? Manipulating diet for the modulation of inflammation. Am J Rhinol Allergy. 2015 Nov-Dec;29(6):e170-4.
157. Kaspar, Heinrich. Ernährungsmedizin und Diätetik, 12. überarbeitete Auflage, München: Urban & Fischer, 2014.
158. Laidlaw T: A Pilot Study of the Effectiveness of a High Omega-3/Low Omega-6 Treatment Diet for Treating Aspirin-exacerbated Respiratory Disease [online] https://clinicaltrials.gov/ct2/show/NCT02064738 [17.02.2018]
159. Healy E, Newell L, Howarth P, Friedmann PS. Control of salicylate intolerance with fish oils. Br J Dermatol. 2008 Dec;159(6):1368-9.
160. Race S: The Salicylate Handbook – Your guide to understanding salicylate sensitivity. Tigmor Books, 2012.
161. Baenkler H-W „Salizylat-Intoleranz – eine besondere Systemerkrankung“. Baenkler H-W (Hg.): Salizylat-Intoleranz. Dustri-Verlag, 2019.
162. Molderungs G J „Der neue Stellenwert der Mastzelle im Immunsystem“. Baenkler H-W (Hg.): Salizylat-Intoleranz. Dustri-Verlag, 2019.